Growth hormone inhibitors in prostate cancer: A systematic analysis

Urologia Internationalis

Volumn 81, Issue 1, 2008, Pages 17-22

  Schmid, Hans Peter ^a   Gregorin, Joel ^a   Altwein, Jens E ^b  

^a Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Growth hormone inhibitors; Prostate cancer; Somatostatins

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANDROGEN; ANGIOPEPTIN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CHROMOGRANIN A; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE; ESTROGEN; ETHINYLESTRADIOL; ETOPOSIDE; GONADORELIN DERIVATIVE; GROWTH HORMONE; HORMONE INHIBITOR; INDIUM 111; KETOCONAZOLE; MITOXANTRONE; OCTREOTIDE; PASIREOTIDE; SMS D70; SOMATOSTATIN DERIVATIVE; VAPREOTIDE; YTTRIUM 90;

ARTICLE; BIBLIOGRAPHIC DATABASE; BLOATING; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INFORMATION PROCESSING; INFORMATION RETRIEVAL; MEDLINE; MONOTHERAPY; NAUSEA; NEUROTOXICITY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VISCERAL METASTASIS;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; GONADOTROPIN-RELEASING HORMONE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 47949132847     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000137635     Document Type: Article

References (43)

1. Hellerstedt BA, Pienta KJ: The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52:154-179.
2. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid H-P, van Poppel H, Wolff J, Zattoni F: EAU guidelines on prostate cancer. Eur Urol 2005;48:546-551.
3. Schmid H-P, Keuler FU, Altwein JE: Rising prostate-specific antigen after primary treatment of prostate cancer: sequential hormone manipulation. Urol Int 2007;79:95-104.
4. Linja MJ, Visakorpi T: Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 2004;94:255-264.
5. Hochberg Z, Pacak K, Chrousos GP: Endocrine withdrawal syndromes. Endocr Rev 2003;24:523-538.
6. Setlur SR, Rubin MA: Current thoughts on the role of the androgen receptor and prostate cancer progression. Adv Anat Pathol 2005;12:265-270.
7. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrum AS: Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175:27-34.
8. Mosca A, Dogliotti L, Berruti A, Lamberts SW, Hofland LJ: Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: prostate cancer. Dig Liver Dis 2004;36(suppl 1):S60-S67.
9. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM, Hsiung HM, Becker GW, Neubauer BL: Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst 1999;91:1663-1669.
10. Koutsilieris M, Mitsiades C, Lembessis P, Sourla A: Cancer and bone repair mechanism: clinical applications for hormone refractory prostate cancer. J Musculoskelet Neuronal Interact 2000;1:15-17.
11. Gennigens C, Menetrier-Caux C, Droz JP: Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006;58:124-145.
12. Sciarra A, Bosman C, Monti G, Gentile V, Gomez AM, Ciccariello M, Pastore A, Salvatori G, Fattore F, di Silverio F: Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma. J Urol 2004;172:1775-1783.
13. Chatterjee B: The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 2003;253:89-101.
14. Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T: Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 1999;189:559-563.
15. Sciarra A, Cardi A, Dattilo C, Mariotti G, di Monaco F, di Silverio F: New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract 2006;60:462-470.
16. Krulich L, Dhariwal AP, Mc Cann SM: Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968;83:783-790.
17. Viollet C, Prevost G, Maubert E, Faivre-Baumann A, Gardette R, Kordon C, Loudes C, Slama A, Epelbaum J: Molecular pharmacology of somatostatin receptors. Fundam Clin Pharmacol 1995;9:107-113.
18. Hansson J, Bjartell A, Gadaleanu V, Dizeyi N, Abrahamsson PA: Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 2002;53:50-59.
19. Dizeyi N, Konrad L, Bjartell A, Wu H, Gadaleanu V, Hansson J, Helboe L, Abrahamsson PA: Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 2002;7:91-98.
20. Reubi JC: New specific radioligand for one subpopulation of brain somatostatin receptors. Life Sci 1985;36:1826-1836.
21. Lamberts SW, de Herder WW, Hofland LJ: Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 2002;13:451-457.
22. Hejna M, Schmidinger M, Raderer M: The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002;13:653-668.
23. Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A: Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004;10:4398-4405.
24. Schally AV: Oncological applications of somatostatin analogues. Cancer Res 1988;48:6977-6985.
25. Joensuu TK, Nilsson S, Holmberg AR, Marquez M, Tehnhunen M, Saarto T, Joensuu H: Phase I trial on sms-d70 somatostatin analogues in advanced prostate and renal cell cancer. Ann NY Acad Sci 2004;1028:361-374.
26. Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K: Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogues AN-238. Cancer Res 1999;59:1947-1953.
27. Plonowski A, Schally AV, Nagy A, Sun B, Halmos G: Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. Int J Oncol 2002;20:397-402.
28. de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP: Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest 2005;28(suppl):132-136.
29. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, Peck-Radosavljevic M, Hamilton G, Kaserer K, Kofler A, Schlangbauer-Wadl H, Traub T, Virgolini I: DOTA-Ianreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999;140:5136-5148.
30. Kaltsas GA, Papadogias D, Makras P, Grossmann AB: Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005;12:683-699.
31. Logothetis CJ, Hossan EA, Smith TL: SMS 201-995 in the treatment of refractory prostatic carcinoma. Anticancer Res 1994;14:2731-2734.
32. Verhelst J, de Longueville M, Ongena P, Denis L, Mahler C: Octreotide in advanced prostatic cancer relapsing under hormonal treatment. Acta Urol Belg 1994;62:83-88.
33. Vainas G, Pasaitou V, Galaktidou G, Maris K, Christodoulou K, Constantinidis C, Kortsaris AH: The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma. J Exp Clin Cancer Res 1997;16:119-126.
34. Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O: A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer 1995;75:2159-2164.
35. Maulard C, Richaud P, Droz JP, Jessueld D, Dufour-Esquerre F, Housset M: Phase I-II study of the somatostatin analogues Ianreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 1995;36:259-262.
36. Acosta S, Abrahamsson PA: Somatostatin analogue treatment of patients with hormone refractory prostate cancer: first clinical results. Eur Urol 2001;39(suppl):80.
37. Koutsilieris M, Tzanela M, Dimopoulos T: Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate 1999;38:313-316.
38. Koutsilieris M, Mitsiades C, Dimopoulos T, Ionnaidis A, Ntounis A, Lambou T: A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical response to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001;86:5729-5736.
39. Gonzales-Barcena D, Schally AV, Vadillo-Buenfil M, Cortez-Morales A, Hernandez LV, Cardenas-Cornejo I, Comaru-Schally AM: Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. Prostate 2003;56:183-191.
40. Cerulli C, Sciarra A, Salvatori G, di Silverio F: Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablationrefractory prostate cancer. Urology 2004;64:1231.e1- 1231e3.
41. Dimopoulos MA, Kjamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, Alamanis C, Constantinidis C, Koutsilieris M: Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomised phase II study. Urology 2004;63:120-125.
42. Di Silverio F, Sciarra A: Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin A in patients with androgen ablation refractory prostate cancer. J Urol 2003;170:1812-1816.
43. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG: High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000;163:623-629.